Lantern Pharma Inc.
LTRNAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| EF Hutton | maintain | Buy | Aug 10, 2023 |
| EF Hutton | maintain | Buy | Jun 26, 2023 |
| HC Wainwright & Co. | maintain | Neutral | May 18, 2023 |
| EF Hutton | maintain | Buy | Mar 21, 2023 |
| EF Hutton | maintain | Buy | Feb 15, 2023 |
| EF Hutton | maintain | Buy | Nov 1, 2022 |
| HC Wainwright & Co. | maintain | Buy | Mar 11, 2022 |
| HC Wainwright & Co. | maintain | Buy | Nov 2, 2021 |
| HC Wainwright & Co. | maintain | Buy | Oct 7, 2021 |
| Colliers Securities | maintain | Buy | Jul 28, 2020 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.35| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.57 | $-0.38 | — | — |
| May 15, 2026 | $-0.30 | $-0.36 | — | — |
| Mar 30, 2026 | $-0.36 | $-0.46 | — | — |
| Nov 12, 2025 | $-0.39 | $-0.46 | — | — |
| Aug 13, 2025 | $-0.40 | $-0.53 | — | — |
| May 15, 2025 | $-0.42 | $-0.49 | — | — |
| Mar 27, 2025 | $-0.54 | $-0.51 | $100.7K | — |
| Nov 7, 2024 | $-0.42 | $-0.56 | — | — |
News
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in Taiwan to open the next stage (Part 2) of its Phase 2 HARMONIC™ trial of LP-300. The Taiwan Food and Drug Administration (TFDA) approved the amended protocol earlier in September, and the lead Taiwan site received local Institutional Review Board (IRB) approval on September 29, 2026. The lead site is now open to.
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering.
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern”, the “Company” or “we”), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 3,669,725 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.09 per share (or pre-funded warrant in lieu thereof) in.
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology t
DALLAS--(BUSINESS WIRE)--Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmark.
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, titled "Method for Treating Blood Cancers," with claims directed to the use of the company's drug candidate LP‑284 to treat patients with mantle cell lymphoma (.
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it will host a live webinar on Wednesday, September 23, 2026 at 12:30 PM Eastern to present the business model, development roadmap, and value proposition of Open-Medicine AI (OMAI), the company's wholly owned subsidiary building a multi-agentic AI platform for end-to-end therapeuti.
Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update.